Seminar 2026

AI investment in clinical trials is accelerating, but clear, measurable returns are still difficult to define. Pharma/Biotech companies are waiting to see if there is an ROI to shed some uncertainty over scaling and success. What early signals of ROI from AI in clinical development look like today, and where evidence is still limited How organizations are defining and measuring value across efficiency, quality, and decision-making Where expectations may be ahead of reality and what timelines for impact are realistic What ROI could look like as AI adoption matures over the next 6–12 months